Latest news with #MicrobaLifeSciencesLimited
Business Insider
29-05-2025
- Business
- Business Insider
Microba Life Sciences Limited (MAP) Receives a Buy from Canaccord Genuity
Canaccord Genuity analyst Elyse Shapiro maintained a Buy rating on Microba Life Sciences Limited (MAP – Research Report) yesterday and set a price target of A$0.26. The company's shares closed today at A$0.15. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Shapiro covers the Healthcare sector, focusing on stocks such as Mayne Pharma Group, Immutep Ltd, and Neuren Pharmaceuticals Limited. According to TipRanks, Shapiro has an average return of -13.9% and a 32.84% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Microba Life Sciences Limited with a A$0.34 average price target.
Business Wire
15-05-2025
- Health
- Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients
BRISBANE, Australia--(BUSINESS WIRE)-- Microba Life Sciences Limited (ASX: MAP) ('Microba' or the 'Company'), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. 'MetaXplore is a powerful addition to the diagnostic toolbox for patients with persistent gastrointestinal symptoms..." Commented Associate Professor Graham Radford-Smith. These results highlight the clinical value of MetaXplore test results in advancing outcomes for patients with chronic lower gastrointestinal disorders, highlighting the potential to reshape clinical management of these conditions and set a new standard of care. An in-depth analysis of billing and claims data for MetaXplore target patient populations, has estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia. MetaXplore™ Identifies Actionable Results in the Majority of Cases Analysis conducted by Microba of 4,616 MetaXplore™ GI Plus patients test results from Australia revealed that 71.4% (3,295) of reports identified actionable results. 41.9% (1,932) of reports showed abnormal microbiome markers linked to gastrointestinal health, including 7% that were positive for a pathogen species that can cause GI abnormal microbiome markers can be addressed via evidence-based targeted nutritional or lifestyle changes, or antimicrobial therapy (antibiotics) when a pathogen is identified. 9.9% (459) of reports tested positive for a gastrointestinal marker (e.g. inflammation, pancreatic insufficiency, or faecal occult blood), prompting further diagnostic workup and supporting management of conditions such as inflammatory bowel disease (IBD), colorectal cancer, or pancreatic insufficiency via pharmacological treatment including biologics 19.6% (904) of reports tested positive for multiple markers (microbiome and gastrointestinal), addressed via a personalised mix of pharmacological, nutritional and lifestyle modification strategies These results demonstrate how the MetaXplore test provides critical new insights to enable clinicians to apply personalised, multi-dimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal disorders. In cases where no significant findings were identified, the results can help clinicians to rule out and narrow potential causes of the patients' gastrointestinal symptoms, and may suggest psychological or neurological contributors to symptoms which empower additional clinical pathways. This study is ongoing, supports the integration of MetaXplore testing into standard care protocols, and is expected to be published in peer-reviewed journals. MetaXplore™ Patients Report Measurable Health Benefits A separate study of 84 patients by Microba who received MetaXplore-guided care found that 65.5% reported health improvements after following their clinician's recommendations: 22.6% reported significant improvement 42.9% noticed some improvement These preliminary results highlight how the MetaXplore test results and personalised, targeted interventions improve patient outcomes. This initial patient survey data demonstrates the relationship between MetaXplore positive test results and improved patient outcomes, supporting the clinical impact Microba is seeing with clinicians and patients, and setting up for larger planned studies measuring patient outcomes. Associate Professor Graham Radford-Smith, a leading gastroenterologist and expert in functional GI disorders, is currently working with Microba on a clinical utility study of MetaXplore™ in his practice. He commented: 'MetaXplore is a powerful addition to the diagnostic toolbox for patients with persistent gastrointestinal symptoms. It enables me to objectively identify microbiome dysbiosis, evaluate dietary quality, and direct patients toward evidence-based nutritional strategies. Importantly, it helps differentiate patients with normal GI and microbial profiles who may benefit from psychological support rather than further invasive testing or pharmacological escalation.' Addressable market of over 82 million patients with lower gastrointestinal symptoms An in-depth analysis of billing and claims data for MetaXplore target patient populations, estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia 1. This population consists of patients with chronic diarrhoea or non-specific abdominal symptoms such as pain, bloating and constipation, including patients characterised with Irritable Bowel Syndrome (IBS) or diagnosed with Inflammatory Bowel Disease (IBD). The current standard of care for these patients is leading to an estimated 50% of patients not getting a resolution to their symptoms 2, necessitating a radical advancement in the tools available to support these patients and improve outcomes. MetaXplore™ is supporting clinicians to manage and improve outcomes for these patients through a comprehensive test that can: Assess structural and functional abnormalities in the microbiome Detect overlooked harmful gut bacteria (pathogens), inflammatory or insufficiency markers Identify evidence based, personalised pharmacological, nutritional and lifestyle modification strategies Support patient motivation and adherence to pharmacological, nutritional and lifestyle modifications May support identification of cases where mental health support may be appropriate As the burden of chronic digestive disorders continues to grow, MetaXplore offers a scalable, evidence-based new solution to evaluate and clinically manage GI dysfunction. About Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
Yahoo
05-05-2025
- Business
- Yahoo
Some Analysts Just Cut Their Microba Life Sciences Limited (ASX:MAP) Estimates
The analysts covering Microba Life Sciences Limited (ASX:MAP) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well. We've discovered 3 warning signs about Microba Life Sciences. View them for free. After the downgrade, the consensus from Microba Life Sciences' dual analysts is for revenues of AU$15m in 2025, which would reflect a considerable 9.5% decline in sales compared to the last year of performance. The loss per share is expected to ameliorate slightly, reducing to AU$0.029. However, before this estimates update, the consensus had been expecting revenues of AU$18m and AU$0.029 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers. View our latest analysis for Microba Life Sciences the analysts have cut their price target 17% to AU$0.29 per share, signalling that the declining revenue and ongoing losses are contributing to the lower valuation. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 18% by the end of 2025. This indicates a significant reduction from annual growth of 51% over the last three years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 9.6% per year. It's pretty clear that Microba Life Sciences' revenues are expected to perform substantially worse than the wider industry. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Microba Life Sciences' revenues are expected to grow slower than the wider market. Furthermore, there was a cut to the price target, suggesting that the latest news has led to more pessimism about the intrinsic value of the business. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Microba Life Sciences going forwards. Still, the long-term prospects of the business are much more relevant than next year's earnings. At least one analyst has provided forecasts out to 2027, which can be seen for free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Business Insider
01-05-2025
- Business
- Business Insider
Morgans Keeps Their Buy Rating on Microba Life Sciences Limited (MAP)
In a report released today, Iain Wilkie from Morgans maintained a Buy rating on Microba Life Sciences Limited (MAP – Research Report), with a price target of A$0.32. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wilkie is an analyst with an average return of -11.3% and a 29.69% success rate. Wilkie covers the Healthcare sector, focusing on stocks such as Nanosonics Limited, Pro Medicus Limited, and Mach7 Technologies. Currently, the analyst consensus on Microba Life Sciences Limited is a Moderate Buy with an average price target of A$0.35. The company has a one-year high of A$0.33 and a one-year low of A$0.15. Currently, Microba Life Sciences Limited has an average volume of 180.3K.
